Characterization of a novel bacteriophage endolysin (LysAB1245) with extended lytic activity against distinct capsular types associated with Acinetobacter baumannii resistance
PLOS ONE · 02.01.2024 · 19 (1) · e0296453
DOI: 10.1371/journal.pone.0296453 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 02.01.2024. Verfasst von Rosesathorn Soontarach und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science, Center of Antimicrobial Biomaterial Innovation-Southeast Asia, Prince of Songkla University, Songkhla, Thailand. Hauptthemen laut MEDLINE: Bacteriophages, Acinetobacter baumannii. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Council of Thailand, Postdoctoral Fellowship from Prince of Songkla University.
Abstract (Originalsprache)
Capsular polysaccharides are considered as major virulence factors associated with the ability of multidrug-resistant (MDR) Acinetobacter baumannii to cause severe infections. In this study, LysAB1245, a novel bacteriophage-encoded endolysin consisting of a lysozyme-like domain from phage T1245 was successfully expressed, purified, and evaluated for its antibacterial activity against distinct capsular types associated with A . baumannii resistance. The results revealed a broad spectrum activity of LysAB1245 against all clinical MDR A . baumannii isolates belonging to capsular type (KL) 2, 3, 6, 10, 47, 49, and 52 and A . baumannii ATCC 19606. At 2 h following the treatment with 1.7 unit/reaction of LysAB1245, more than 3 log reduction in the numbers of bacterial survival was observed. In addition, LysAB1245 displayed rapid bactericidal activity within 30 min (nearly 3 log CFU/mL of bacterial reduction). Thermostability assay indicated that LysAB1245 was stable over a broad range of temperature from 4 to 70°C, while pH sensitivity assay demonstrated a wide range of pH from 4.5 to 10.5. Furthermore, both minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of LysAB1245 against all MDR A . baumannii isolates and A . baumannii ATCC 19606 were 4.21 μg/mL (0.1 unit/reaction). Conclusively, these results suggest that LysAB1245 possesses potential application for the treatment of nosocomial MDR A . baumannii infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Science, Center of Antimicrobial Biomaterial Innovation-Southeast Asia, Prince of Songkla University, Songkhla, Thailand.
- Faculty of Medicine, Department of Internal Medicine, Division of Infectious Diseases, Prince of Songkla University, Songkhla, Thailand.
- Faculty of Allied Health Sciences, Graduate in Biomedical Sciences, Thammasat University, Pathum Thani, Thailand.
- Faculty of Science, Division of Biological Science, Program in Molecular Biology and Bioinformatics, Prince of Songkla University, Songkhla, Thailand.
ORCID-Profile: Alisa Nakkaew, Sarunyou Chusri
Förderung
- National Research Council of Thailand
- Postdoctoral Fellowship from Prince of Songkla University
Zitieren
APA
Soontarach, R., Srimanote, P., Arechanajan, B., Nakkaew, A., Voravuthikunchai, S. P., & Chusri, S. (2024). Characterization of a novel bacteriophage endolysin (LysAB1245) with extended lytic activity against distinct capsular types associated with Acinetobacter baumannii resistance. PLOS ONE, 19(1), e0296453. https://doi.org/10.1371/journal.pone.0296453
Vancouver
Soontarach R, Srimanote P, Arechanajan B, Nakkaew A, Voravuthikunchai SP, Chusri S. Characterization of a novel bacteriophage endolysin (LysAB1245) with extended lytic activity against distinct capsular types associated with Acinetobacter baumannii resistance. PLOS ONE. 2024;19(1):e0296453. doi:10.1371/journal.pone.0296453
BibTeX
@article{Soontarach2024,
author = {Soontarach, Rosesathorn and Srimanote, Potjanee and Arechanajan, Buppa and Nakkaew, Alisa and Voravuthikunchai, Supayang Piyawan and Chusri, Sarunyou},
title = {Characterization of a novel bacteriophage endolysin (LysAB1245) with extended lytic activity against distinct capsular types associated with Acinetobacter baumannii resistance},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {1},
pages = {e0296453},
doi = {10.1371/journal.pone.0296453}
}
EUVIMED